Our previous studies have also indicated that upregulated Rhbdf2 triggered by HFD significantly drives progression of NAFLD/NASH pathological phenotype in vivo, revealing a potential treatment prospect of Rhbdf2 in liver steatosis-associated metabolic disorders15,32. This evidence concerns the gene RHBDF2 and metabolic dysfunction-associated steatotic liver disease.